These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31884129)

  • 1. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Reale ML; Chiari R; Tiseo M; Vitiello F; Barbieri F; Cortinovis D; Ceresoli GL; Finocchiaro G; Romano GD; Piovano PL; Del Conte A; Borra G; Verderame F; Scotti V; Nonnis D; Galetta D; Sergi C; Migliorino MR; Tonini G; Cecere F; Berardi R; Pino MS; Martelli O; Gelibter A; Carta A; Vattemi E; Pagano M; Zullo A; Ferrari S; Rossi A; Novello S
    Lung Cancer; 2020 Feb; 140():71-79. PubMed ID: 31884129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
    Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
    Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
    Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
    Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.
    Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
    Zeng L; Xiao L; Jiang W; Yang H; Hu D; Xia C; Li Y; Zhou C; Xiong Y; Liu L; Liao D; Guan R; Li K; Wang J; Zhang Y; Yang N; Mansfield AS
    Lung Cancer; 2020 Mar; 141():82-88. PubMed ID: 31982639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
    Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G
    Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
    BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.
    Assi H; Tfayli A; Assaf N; Daya SA; Bidikian AH; Kawsarani D; Fermanian P; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Aug; 46(4):3671-3676. PubMed ID: 31147859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
    Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
    Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
    Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
    Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
    Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
    Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
    BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.